ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

MESO Mesoblast Limited

7.21
0.61 (9.24%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Mesoblast Limited MESO NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.61 9.24% 7.21 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
7.06 7.00 7.3732 7.21 6.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202420:05GLOBEAppendix 4c Quarterly Activity Report for Quarter Ended..
26/3/202408:25APSFDA Commentary Sends Biotech Soaring During Premarket Hours
25/3/202421:34GLOBEUnited States Food & Drug Administration (FDA) Notifies..
13/3/202418:30GLOBEMesoblast Successfully Completes Placement and Accelerated..
10/3/202418:54GLOBEUnited States Food & Drug Administration (FDA) Supports..
28/2/202416:57GLOBEMesoblast Reports Financial Results and Operational Update..
26/2/202406:00GLOBEMesoblast Financial Results and Corporate Update Webcast
14/2/202418:46GLOBEUnited States Food & Drug Administration (FDA) Grants..
31/1/202420:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202420:13GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended..
18/1/202418:28DJNMesoblast Gets FDA's Special Pediatric Designation for..
18/1/202417:36GLOBEUnited States Food & Drug Administration (FDA) Grants..
16/1/202405:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/1/202420:57EDGAR2Form F-6 POS - Post-effective amendments for immediately..
22/12/202316:13EDGAR2Form F-6 POS - Post-effective amendments for immediately..
26/11/202317:56GLOBEMesoblast Files for Orphan Drug and Pediatric Rare Disease..
22/11/202312:35APSBiotech Shares Soar Following Major Announcement
21/11/202317:32GLOBEMesoblast Partners With Blood and Marrow Transplant Clinical..
30/10/202319:04GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended..
26/9/202305:18GLOBEJane Bell AM Appointed Chair of Mesoblast Audit and Risk..
21/9/202302:30GLOBEKey Outcomes From FDA Type A Meeting and Mesoblast Next..
06/9/202305:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/8/202318:07GLOBEMesoblast Reports Financial Results and Operational Update..
29/8/202306:00GLOBEMesoblast Financial Results and Corporate Update Webcast
04/8/202308:03DJNMesoblast ADSs Plunge Premarket on Latest FDA Rejection
03/8/202319:10GLOBEMesoblast Receives Complete Response From U.S. Food and Drug..
30/7/202319:31GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended June..
04/6/202319:21GLOBEMesoblast Director Philip R. Krause, M.D., Appointed to..
25/5/202318:28GLOBEMesoblast Reports Operational and Financial Highlights for..
24/5/202306:00GLOBEMesoblast Financial Results and Corporate Update Webcast

Su Consulta Reciente

Delayed Upgrade Clock